Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 259

1.

From the Editor's Desk…: October 2019.

Moreau R, Bataller R, Berg T, Lotersztajn S, Zucman-Rossi J, Jalan R.

J Hepatol. 2019 Oct;71(4):641-644. doi: 10.1016/j.jhep.2019.07.017. No abstract available.

PMID:
31570143
2.

From the Editor's Desk: September 2019.

Moreau R, Bataller R, Berg T, Lotersztajn S, Zucman-Rossi J, Jalan R.

J Hepatol. 2019 Sep;71(3):449-452. doi: 10.1016/j.jhep.2019.06.016. No abstract available.

PMID:
31422825
3.

Natural history of liver adenomatosis: a long-term observational study.

Barbier L, Nault JC, Dujardin F, Scotto B, Besson M, de Muret A, Bourlier P, Zucman-Rossi J, Salamé E, Bacq Y.

J Hepatol. 2019 Aug 13. pii: S0168-8278(19)30470-2. doi: 10.1016/j.jhep.2019.08.004. [Epub ahead of print]

PMID:
31419515
4.

Immunogenomics of Metastatic Clear-Cell Renal Cell Carcinoma: Remarkable Response to Nivolumab in a Patient With a Pathogenic Germ Line BRCA1 Mutation.

Beulque Y, Deleu AL, Punie K, De Wever L, Baldewijns M, Caruso S, Couchy G, Zucman-Rossi J, Beuselinck B.

Clin Genitourin Cancer. 2019 Jul 11. pii: S1558-7673(19)30202-2. doi: 10.1016/j.clgc.2019.06.013. [Epub ahead of print] No abstract available.

PMID:
31378579
5.

Adeno-associated virus in the liver: natural history and consequences in tumour development.

La Bella T, Imbeaud S, Peneau C, Mami I, Datta S, Bayard Q, Caruso S, Hirsch TZ, Calderaro J, Morcrette G, Guettier C, Paradis V, Amaddeo G, Laurent A, Possenti L, Chiche L, Bioulac-Sage P, Blanc JF, Letouze E, Nault JC, Zucman-Rossi J.

Gut. 2019 Aug 2. pii: gutjnl-2019-318281. doi: 10.1136/gutjnl-2019-318281. [Epub ahead of print]

PMID:
31375600
6.

ESM1 as a Marker of Macrotrabecular-Massive Hepatocellular Carcinoma.

Calderaro J, Meunier L, Nguyen CT, Boubaya M, Caruso S, Luciani A, Amaddeo G, Regnault H, Nault JC, Cohen J, Oberti F, Michalak S, Bouattour M, Vilgrain V, Pageaux GP, Ramos J, Barget N, Guiu B, Paradis V, Aubé C, Laurent A, Pawlotsky JM, Ganne-Carrié N, Zucman-Rossi J, Seror O, Ziol M.

Clin Cancer Res. 2019 Oct 1;25(19):5859-5865. doi: 10.1158/1078-0432.CCR-19-0859. Epub 2019 Jul 29.

PMID:
31358545
7.

From the Editor's desk…: August 2019.

Moreau R, Bataller R, Berg T, Lotersztajn S, Zucman-Rossi J, Jalan R.

J Hepatol. 2019 Aug;71(2):231-234. doi: 10.1016/j.jhep.2019.06.007. No abstract available.

PMID:
31319937
8.

The role of telomeres and telomerase in cirrhosis and liver cancer.

Nault JC, Ningarhari M, Rebouissou S, Zucman-Rossi J.

Nat Rev Gastroenterol Hepatol. 2019 Sep;16(9):544-558. doi: 10.1038/s41575-019-0165-3. Epub 2019 Jun 28. Review.

PMID:
31253940
9.

Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors.

Verbiest A, Renders I, Caruso S, Couchy G, Job S, Laenen A, Verkarre V, Rioux-Leclercq N, Schöffski P, Vano Y, Elaidi RT, Lerut E, Albersen M, Oudard S, Fridman WH, Sautès-Fridman C, Albigès L, Wozniak A, Zucman-Rossi J, Beuselinck B.

Clin Genitourin Cancer. 2019 May 25. pii: S1558-7673(19)30147-8. doi: 10.1016/j.clgc.2019.05.009. [Epub ahead of print]

PMID:
31229459
10.

From the Editor's desk…: July 2019.

Moreau R, Bataller R, Berg T, Lotersztajn S, Zucman-Rossi J, Jalan R.

J Hepatol. 2019 Jul;71(1):1-4. doi: 10.1016/j.jhep.2019.05.001. No abstract available.

PMID:
31208533
11.

Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma.

Nault JC, Martin Y, Caruso S, Hirsch TZ, Bayard Q, Calderaro J, Charpy C, Copie-Bergman C, Ziol M, Bioulac-Sage P, Couchy G, Blanc JF, Nahon P, Amaddeo G, Ganne-Carrie N, Morcrette G, Chiche L, Duvoux C, Faivre S, Laurent A, Imbeaud S, Rebouissou S, Llovet JM, Seror O, Letouzé E, Zucman-Rossi J.

Hepatology. 2019 Jun 17. doi: 10.1002/hep.30811. [Epub ahead of print]

PMID:
31206197
12.

Molecular and histological correlations in liver cancer.

Calderaro J, Ziol M, Paradis V, Zucman-Rossi J.

J Hepatol. 2019 Sep;71(3):616-630. doi: 10.1016/j.jhep.2019.06.001. Epub 2019 Jun 10. Review.

PMID:
31195064
13.

Hepatocellular Carcinomas With Mutational Activation of Beta-Catenin Require Choline and Can Be Detected by Positron Emission Tomography.

Gougelet A, Sartor C, Senni N, Calderaro J, Fartoux L, Lequoy M, Wendum D, Talbot JN, Prignon A, Chalaye J, Imbeaud S, Zucman-Rossi J, Tordjmann T, Godard C, Bossard P, Rosmorduc O, Amaddeo G, Colnot S.

Gastroenterology. 2019 Sep;157(3):807-822. doi: 10.1053/j.gastro.2019.05.069. Epub 2019 Jun 10.

PMID:
31194980
14.

RSPO2 abnormal transcripts result from read-through in liver tumours with high ß-catenin activation and CTNNB1 mutations.

Bayard Q, Nault JC, Zucman-Rossi J.

Gut. 2019 Jun 1. pii: gutjnl-2019-319089. doi: 10.1136/gutjnl-2019-319089. [Epub ahead of print] No abstract available.

PMID:
31154392
15.

From the Editor's desk…: June 2019.

Moreau R, Bataller R, Berg T, Lotersztajn S, Zucman-Rossi J, Jalan R.

J Hepatol. 2019 Jun;70(6):1039-1042. doi: 10.1016/j.jhep.2019.03.023. No abstract available.

PMID:
31103094
16.

APC germline hepatoblastomas demonstrate cisplatin-induced intratumor tertiary lymphoid structures.

Morcrette G, Hirsch TZ, Badour E, Pilet J, Caruso S, Calderaro J, Martin Y, Imbeaud S, Letouzé E, Rebouissou S, Branchereau S, Taque S, Chardot C, Guettier C, Scoazec JY, Fabre M, Brugières L, Zucman-Rossi J.

Oncoimmunology. 2019 Mar 28;8(6):e1583547. doi: 10.1080/2162402X.2019.1583547. eCollection 2019.

17.

Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response.

Caruso S, Calatayud AL, Pilet J, La Bella T, Rekik S, Imbeaud S, Letouzé E, Meunier L, Bayard Q, Rohr-Udilova N, Péneau C, Grasl-Kraupp B, de Koning L, Ouine B, Bioulac-Sage P, Couchy G, Calderaro J, Nault JC, Zucman-Rossi J, Rebouissou S.

Gastroenterology. 2019 Sep;157(3):760-776. doi: 10.1053/j.gastro.2019.05.001. Epub 2019 May 4.

PMID:
31063779
18.

Polyploidy spectrum: a new marker in HCC classification.

Bou-Nader M, Caruso S, Donne R, Celton-Morizur S, Calderaro J, Gentric G, Cadoux M, L'Hermitte A, Klein C, Guilbert T, Albuquerque M, Couchy G, Paradis V, Couty JP, Zucman-Rossi J, Desdouets C.

Gut. 2019 Apr 12. pii: gutjnl-2018-318021. doi: 10.1136/gutjnl-2018-318021. [Epub ahead of print]

19.

From the Editor's desk…: May 2019.

Moreau R, Bataller R, Berg T, Lotersztajn S, Zucman-Rossi J, Jalan R.

J Hepatol. 2019 May;70(5):819-821. doi: 10.1016/j.jhep.2019.02.017. No abstract available.

PMID:
30979393
20.

Dynamics and predicted drug response of a gene network linking dedifferentiation with beta-catenin dysfunction in hepatocellular carcinoma.

Gérard C, Di-Luoffo M, Gonay L, Caruso S, Couchy G, Loriot A, Castven D, Tao J, Konobrocka K, Cordi S, Monga SP, Hanert E, Marquardt JU, Zucman-Rossi J, Lemaigre FP.

J Hepatol. 2019 Aug;71(2):323-332. doi: 10.1016/j.jhep.2019.03.024. Epub 2019 Apr 4.

PMID:
30953666
21.

A 17-Beta-Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease.

Yang J, Trépo E, Nahon P, Cao Q, Moreno C, Letouzé E, Imbeaud S, Bayard Q, Gustot T, Deviere J, Bioulac-Sage P, Calderaro J, Ganne-Carrié N, Laurent A, Blanc JF, Guyot E, Sutton A, Ziol M, Zucman-Rossi J, Nault JC.

Hepatology. 2019 Jul;70(1):231-240. doi: 10.1002/hep.30623. Epub 2019 Apr 25.

PMID:
30908678
22.

Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications.

Blum Y, Meiller C, Quetel L, Elarouci N, Ayadi M, Tashtanbaeva D, Armenoult L, Montagne F, Tranchant R, Renier A, de Koning L, Copin MC, Hofman P, Hofman V, Porte H, Le Pimpec-Barthes F, Zucman-Rossi J, Jaurand MC, de Reyniès A, Jean D.

Nat Commun. 2019 Mar 22;10(1):1333. doi: 10.1038/s41467-019-09307-6.

23.

From the Editor's desk…: April 2018.

Moreau R, Bataller R, Berg T, Lotersztajn S, Zucman-Rossi J, Jalan R.

J Hepatol. 2019 Apr;70(4):583-586. doi: 10.1016/j.jhep.2019.02.001. No abstract available.

PMID:
30885295
24.

From the Editor's desk....: March 2019.

Moreau R, Bataller R, Berg T, Lotersztajn S, Zucman-Rossi J, Jalan R.

J Hepatol. 2019 Mar;70(3):335-338. doi: 10.1016/j.jhep.2018.12.020. No abstract available.

PMID:
30777172
25.

Inhibiting Glutamine-Dependent mTORC1 Activation Ameliorates Liver Cancers Driven by β-Catenin Mutations.

Adebayo Michael AO, Ko S, Tao J, Moghe A, Yang H, Xu M, Russell JO, Pradhan-Sundd T, Liu S, Singh S, Poddar M, Monga JS, Liu P, Oertel M, Ranganathan S, Singhi A, Rebouissou S, Zucman-Rossi J, Ribback S, Calvisi D, Qvartskhava N, Görg B, Häussinger D, Chen X, Monga SP.

Cell Metab. 2019 May 7;29(5):1135-1150.e6. doi: 10.1016/j.cmet.2019.01.002. Epub 2019 Jan 31.

PMID:
30713111
26.

From the Editor's Desk: January 2019.

Moreau R, Bataller R, Berg T, Lotersztajn S, Zucman-Rossi J, Jalan R.

J Hepatol. 2019 Jan;70(1):1-4. doi: 10.1016/j.jhep.2018.11.002. No abstract available.

PMID:
30558742
27.

Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress.

Bayard Q, Meunier L, Peneau C, Renault V, Shinde J, Nault JC, Mami I, Couchy G, Amaddeo G, Tubacher E, Bacq D, Meyer V, La Bella T, Debaillon-Vesque A, Bioulac-Sage P, Seror O, Blanc JF, Calderaro J, Deleuze JF, Imbeaud S, Zucman-Rossi J, Letouzé E.

Nat Commun. 2018 Dec 7;9(1):5235. doi: 10.1038/s41467-018-07552-9.

28.

Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib.

Vanmechelen M, Lambrechts D, Van Brussel T, Verbiest A, Couchy G, Schöffski P, Dumez H, Debruyne PR, Lerut E, Machiels JP, Richard V, Albersen M, Verschaeve V, Oudard S, Méjean A, Wolter P, Zucman-Rossi J, Beuselinck B.

Clin Genitourin Cancer. 2019 Apr;17(2):e235-e246. doi: 10.1016/j.clgc.2018.11.002. Epub 2018 Nov 16.

PMID:
30527746
29.

Assessment of signaling pathway inhibitors and identification of predictive biomarkers in malignant pleural mesothelioma.

Tranchant R, Quetel L, Montagne F, De Wolf J, Meiller C, De Koning L, Le Pimpec-Barthes F, Zucman-Rossi J, Jaurand MC, Jean D.

Lung Cancer. 2018 Dec;126:15-24. doi: 10.1016/j.lungcan.2018.10.015. Epub 2018 Oct 16.

PMID:
30527180
30.

Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy.

Dhanasekaran R, Nault JC, Roberts LR, Zucman-Rossi J.

Gastroenterology. 2019 Jan;156(2):492-509. doi: 10.1053/j.gastro.2018.11.001. Epub 2018 Nov 4. Review.

PMID:
30404026
31.

PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases.

Yang J, Trépo E, Nahon P, Cao Q, Moreno C, Letouzé E, Imbeaud S, Gustot T, Deviere J, Debette S, Amouyel P, Bioulac-Sage P, Calderaro J, Ganne-Carrié N, Laurent A, Blanc JF, Guyot E, Sutton A, Ziol M, Zucman-Rossi J, Nault JC.

Int J Cancer. 2019 Feb 1;144(3):533-544. doi: 10.1002/ijc.31910. Epub 2018 Nov 9.

PMID:
30289982
32.

Systemic AA Amyloidosis Caused by Inflammatory Hepatocellular Adenoma.

Calderaro J, Letouzé E, Bayard Q, Boulai A, Renault V, Deleuze JF, Bestard O, Franco D, Zafrani ES, Nault JC, Moutschen M, Zucman-Rossi J.

N Engl J Med. 2018 Sep 20;379(12):1178-1180. doi: 10.1056/NEJMc1805673. No abstract available.

PMID:
30231230
33.

Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma.

Calderaro J, Petitprez F, Becht E, Laurent A, Hirsch TZ, Rousseau B, Luciani A, Amaddeo G, Derman J, Charpy C, Zucman-Rossi J, Fridman WH, Sautès-Fridman C.

J Hepatol. 2019 Jan;70(1):58-65. doi: 10.1016/j.jhep.2018.09.003. Epub 2018 Sep 11.

PMID:
30213589
34.

Dietary exacerbation of metabolic stress leads to accelerated hepatic carcinogenesis in glycogen storage disease type Ia.

Gjorgjieva M, Calderaro J, Monteillet L, Silva M, Raffin M, Brevet M, Romestaing C, Roussel D, Zucman-Rossi J, Mithieux G, Rajas F.

J Hepatol. 2018 Nov;69(5):1074-1087. doi: 10.1016/j.jhep.2018.07.017. Epub 2018 Sep 5.

PMID:
30193922
35.

microRNA 193a-5p Regulates Levels of Nucleolar- and Spindle-Associated Protein 1 to Suppress Hepatocarcinogenesis.

Roy S, Hooiveld GJ, Seehawer M, Caruso S, Heinzmann F, Schneider AT, Frank AK, Cardenas DV, Sonntag R, Luedde M, Trautwein C, Stein I, Pikarsky E, Loosen S, Tacke F, Ringelhan M, Avsaroglu SK, Goga A, Buendia MA, Vucur M, Heikenwalder M, Zucman-Rossi J, Zender L, Roderburg C, Luedde T.

Gastroenterology. 2018 Dec;155(6):1951-1966.e26. doi: 10.1053/j.gastro.2018.08.032. Epub 2018 Aug 27.

PMID:
30165047
36.

Lect2 Controls Inflammatory Monocytes to Constrain the Growth and Progression of Hepatocellular Carcinoma.

L'Hermitte A, Pham S, Cadoux M, Couchy G, Caruso S, Anson M, Crain-Denoyelle AM, Celton-Morizur S, Yamagoe S, Zucman-Rossi J, Desdouets C, Couty JP.

Hepatology. 2019 Jan;69(1):160-178. doi: 10.1002/hep.30140. Epub 2018 Dec 22.

PMID:
30070727
37.

Dual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma.

Bárcena-Varela M, Caruso S, Llerena S, Álvarez-Sola G, Uriarte I, Latasa MU, Urtasun R, Rebouissou S, Alvarez L, Jimenez M, Santamaría E, Rodriguez-Ortigosa C, Mazza G, Rombouts K, San José-Eneriz E, Rabal O, Agirre X, Iraburu M, Santos-Laso A, Banales JM, Zucman-Rossi J, Prósper F, Oyarzabal J, Berasain C, Ávila MA, Fernández-Barrena MG.

Hepatology. 2019 Feb;69(2):587-603. doi: 10.1002/hep.30168. Epub 2019 Jan 4.

PMID:
30014490
38.

Liver Cancer Initiation Requires p53 Inhibition by CD44-Enhanced Growth Factor Signaling.

Dhar D, Antonucci L, Nakagawa H, Kim JY, Glitzner E, Caruso S, Shalapour S, Yang L, Valasek MA, Lee S, Minnich K, Seki E, Tuckermann J, Sibilia M, Zucman-Rossi J, Karin M.

Cancer Cell. 2018 Jun 11;33(6):1061-1077.e6. doi: 10.1016/j.ccell.2018.05.003.

39.

The clinical implications of G1-G6 transcriptomic signature and 5-gene score in Korean patients with hepatocellular carcinoma.

Ahn SM, Haq F, Park I, Nault JC, Zucman-Rossi J, Yu E.

BMC Cancer. 2018 May 18;18(1):571. doi: 10.1186/s12885-018-4192-1.

40.

Palimpsest: an R package for studying mutational and structural variant signatures along clonal evolution in cancer.

Shinde J, Bayard Q, Imbeaud S, Hirsch TZ, Liu F, Renault V, Zucman-Rossi J, Letouzé E.

Bioinformatics. 2018 Oct 1;34(19):3380-3381. doi: 10.1093/bioinformatics/bty388.

PMID:
29771315
41.

Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study.

Costentin CE, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, Di Martino V, Sutton A, Letouzé E, Imbeaud S, Zucman-Rossi J, Audureau E, Roudot-Thoraval F, Nahon P; ANRS CO12 CirVir Group.

Gastroenterology. 2018 Aug;155(2):431-442.e10. doi: 10.1053/j.gastro.2018.04.027. Epub 2018 May 3.

PMID:
29729258
42.

Argininosuccinate synthase 1 and periportal gene expression in sonic hedgehog hepatocellular adenomas.

Nault JC, Couchy G, Caruso S, Meunier L, Caruana L, Letouzé E, Rebouissou S, Paradis V, Calderaro J, Zucman-Rossi J.

Hepatology. 2018 Sep;68(3):964-976. doi: 10.1002/hep.29884. Epub 2018 Jun 6.

PMID:
29572896
43.

AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.

Abitbol S, Dahmani R, Coulouarn C, Ragazzon B, Mlecnik B, Senni N, Savall M, Bossard P, Sohier P, Drouet V, Tournier E, Dumont F, Sanson R, Calderaro J, Zucman-Rossi J, Vasseur-Cognet M, Just PA, Terris B, Perret C, Gilgenkrantz H.

J Hepatol. 2018 Jun;68(6):1203-1213. doi: 10.1016/j.jhep.2017.12.018. Epub 2018 Mar 7.

PMID:
29525529
44.

Polymorphisms in the Von Hippel-Lindau Gene Are Associated With Overall Survival in Metastatic Clear-Cell Renal-Cell Carcinoma Patients Treated With VEGFR Tyrosine Kinase Inhibitors.

Verbiest A, Lambrechts D, Van Brussel T, Couchy G, Wozniak A, Méjean A, Lerut E, Oudard S, Verkarre V, Job S, de Reynies A, Machiels JP, Patard JJ, Zucman-Rossi J, Beuselinck B.

Clin Genitourin Cancer. 2018 Aug;16(4):266-273. doi: 10.1016/j.clgc.2018.01.013. Epub 2018 Feb 5.

PMID:
29503246
45.

Molecular Subtypes of Clear-cell Renal Cell Carcinoma are Prognostic for Outcome After Complete Metastasectomy.

Verbiest A, Couchy G, Job S, Caruana L, Lerut E, Oyen R, de Reyniès A, Tosco L, Joniau S, Van Poppel H, Van Raemdonck D, Van Den Eynde K, Wozniak A, Zucman-Rossi J, Beuselinck B.

Eur Urol. 2018 Oct;74(4):474-480. doi: 10.1016/j.eururo.2018.01.042. Epub 2018 Feb 17.

PMID:
29463434
46.

From the Editor's desk...: March 2018.

Moreau R, Bataller R, Berg T, Zucman-Rossi J, Jalan R.

J Hepatol. 2018 Mar;68(3):377-379. doi: 10.1016/j.jhep.2017.12.010. No abstract available.

PMID:
29455797
47.

cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation.

Brunt E, Aishima S, Clavien PA, Fowler K, Goodman Z, Gores G, Gouw A, Kagen A, Klimstra D, Komuta M, Kondo F, Miksad R, Nakano M, Nakanuma Y, Ng I, Paradis V, Nyun Park Y, Quaglia A, Roncalli M, Roskams T, Sakamoto M, Saxena R, Sempoux C, Sirlin C, Stueck A, Thung S, Tsui WMS, Wang XW, Wee A, Yano H, Yeh M, Zen Y, Zucman-Rossi J, Theise N.

Hepatology. 2018 Jul;68(1):113-126. doi: 10.1002/hep.29789. Epub 2018 May 9.

48.

Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance.

Ziol M, Poté N, Amaddeo G, Laurent A, Nault JC, Oberti F, Costentin C, Michalak S, Bouattour M, Francoz C, Pageaux GP, Ramos J, Decaens T, Luciani A, Guiu B, Vilgrain V, Aubé C, Derman J, Charpy C, Zucman-Rossi J, Barget N, Seror O, Ganne-Carrié N, Paradis V, Calderaro J.

Hepatology. 2018 Jul;68(1):103-112. doi: 10.1002/hep.29762. Epub 2018 May 9.

PMID:
29281854
49.

aCNViewer: Comprehensive genome-wide visualization of absolute copy number and copy neutral variations.

Renault V, Tost J, Pichon F, Wang-Renault SF, Letouzé E, Imbeaud S, Zucman-Rossi J, Deleuze JF, How-Kit A.

PLoS One. 2017 Dec 19;12(12):e0189334. doi: 10.1371/journal.pone.0189334. eCollection 2017.

50.

Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting.

Verbiest A, Couchy G, Job S, Zucman-Rossi J, Caruana L, Lerut E, Oyen R, de Reyniès A, Laguerre B, Rioux-Leclercq N, Wozniak A, Joniau S, Van Poppel H, Van Den Eynde K, Beuselinck B.

Clin Genitourin Cancer. 2018 Jun;16(3):e605-e612. doi: 10.1016/j.clgc.2017.10.017. Epub 2017 Nov 7.

PMID:
29239846

Supplemental Content

Loading ...
Support Center